Anticancer and immunosuppressive properties of bacterial prodiginines

Future Microbiology

Volumn 2, Issue 6, 2007, Pages 605-618

  Williamson, Neil R ^a   Fineran, Peter C ^a   Gristwood, Tamzin ^a   Chawrai, Suresh R ^a   Leeper, Finian J ^a   Salmond, George P C ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Apoptosis; Cancer drugs; Immunosuppression; Prodigiosin; Secondary metabolism; Undecylprodigiosin

Indexed keywords

2,2' [3 METHOXY 1' AMYL 5' METHYL 4 (1'' PYRRYL)]DIPYRRYLMETHENE; ANTINEOPLASTIC AGENT; BUTYLCYCLOHEPTYLPRODIGIOSIN; CYCLOPRODIGIOSIN; CYCLOSPORIN A; DOUBLE STRANDED DNA; IMMUNOSUPPRESSIVE AGENT; METACYCLOPRODIGIOSIN; MITOGEN ACTIVATED PROTEIN KINASE; OBATOCLAX; PNU 156804; PRODIGININE DERIVATIVE; PRODIGIOSIN; PYRROLE DERIVATIVE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; UNDECYLPRODIGIOSIN;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; APOPTOSIS; BACTERIAL STRAIN; BIOSYNTHESIS; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PH; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DNA CLEAVAGE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EXPERIMENTAL NEOPLASM; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TARGET CELL;

BACTERIA (MICROORGANISMS);

EID: 37649016653     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.2.6.605     Document Type: Review

References (118)

1. Williamson NR, Fineran PC, Leeper FJ, Salmond GP: The biosynthesis and regulation of bacterial prodiginines. Nat. Rev. Microbiol. 4, 887-899 (2006).
2. Bennett JW, Bentley R: Seeing red: the story of prodigiosin. Adv. Appl. Microbiol. 47, 1-32 (2000).
3. Cullen JC: The miracle of Bolsena: growth of Serratia on sacramental bread and polenta may explain incidents in medieval Italy. ASM News 60, 187-191 (1994).
4. Yu VL: Serratia marcescens: historical perspective and clinical review. N. Engl. J. Med. 300, 887-893 (1979).
5. Rook G: Tumours and Coley's toxins. Nature 357, 545 (1992).
6. Pérez-Tomás R, Montaner B, Llagostera E, Soto-Cerrato V: The prodigiosins, proapoptotic drugs with anticancer properties. Biochem. Pharmacol. 66, 1447-1452 (2003).
7. Pennica D, Nedwin GE, Hayflick JS et al.: Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312, 724-729 (1984).
8. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 72, 3666-3670 (1975).
9. Rapoport HH and Holden KG: The synthesis of prodigiosin. J. Am. Chem. Soc. 84, 635 (1962).
10. Gerber NN: Prodigiosin-like pigments. CRC Crit. Rev. Microbiol. 3, 469-485 (1975).
11. Fürstner A: Chemistry and biology of roseophilin and the prodigiosin alkaloids: a survey of the last 2500 years. Angew. Chem. Int. Ed. Engl. 42, 3582-3603 (2003).
12. Burke C, Thomas T. Egan S, Kjelleberg S: The use of functional genomics for the identification of a gene cluster encoding for the biosynthesis of an antifungal tambjamine in the marine bacterium Pseudoalteromonas tunicata. Environ. Microbiol. 9, 814-818 (2007).
13. Jeong H, Yim JH, Lee C et al.: Genomic blueprint of Hahella chejuensis, a marine microbe producing an algicidal agent. Nucleic Acids Res. 33, 7066-7073 (2005).
14. Demain AL: Why do microorganisms produce antimicrobials? In: Fifty Years of Antimicrobials: Past Perspectives and Future Trends. Hunter PA, Darby GK, Russell NJ (Eds). Society for General Microbiology Symposium 53. Cambridge, UK 205-228 (1995).
15. Nakashima T, Kurachi M, Kato Y, Yamaguchi K, Oda T: Characterization of bacterium isolated from the sediment at coastal area of Omura Bay in Japan and several biological activities of pigment produced by this isolate. Microbiol. linmunol. 49, 407-415 (2005).
16. Williams RP. Quadri SM: The pigment of Serratia. In: The Genus Serratia. Von Graevenitz A, Rubin SJ (Eds). CRC Press Inc., Boca Raton, FL, USA 31-75 (1980).
17. Cerdeño AM, Bibb MJ, Challis GL: Analysis of the prodiginine biosynthesis gene cluster of Streptomyces coelicolor A3(2): new mechanisms for chain initiation and termination in modular multienzymes. Chem. Biol. 8, 817-829 (2001).
18. Stanley AE, Walton LJ, Kourdi Zerikly M. Corre C, Challis GL: Elucidation of the Streptomyces coelicolor pathway to 4-methoxy-2, 2-bipyrrole-5-carboxaldehyde, an Intermediate in prodiginine biosynthesis. Chem. Commun. 3981-3983 (2006).
19. Williamson NR, Simonsen HT, Ahmed RA et al.: Biosynthesis of the red antibiotic, prodigiosip, in Serratia: identification of a novel 2-methyl-3-n-amyl-pyrrole (MAP) - assembly pathway, definition of the terminal condensing enzyme, and implications for undecylprodigiosin biosynthesis in Streptomyces. Mol. Micrabiol. 56, 971-989 (2005).
20. Garneau-Tsodikova S, Dorrestein PC, Kelleher NL, Walsh CT: Protein assembly line components in prodigiosin blosynthesis: characterization of PigA, G, H, I, J. J. Am. Chem. Soc. 128, 12600-12601 (2006).
21. Thomas MG, Burkart MD, Walsh CT: Conversion of L-proline to pyrrolyl-2-carboxyl-S-PCP during undecylprodigiosin and pyoluteorin biosynthesis. Chem. Biol. 9, 171-184 (2002).
22. Harris AK, Williamson NR, Slater H et al.: The Serratia gene cluster encoding biosynthesis of the red antibiotic, prodigiosin, shows species- and strain-dependent genome context variation. Microbiology 150, 3547-3560 (2004).
23. Kim D, Park YK, Lee JS et al.: Analysis of a prodigiosin biosynthetic gene cluster from the marine bacterium Hahella chejuepsis KCTC 2369. J Microbiol. Biotechnol. (2006) (In Press).
24. Walsh CT, Garneau-Tsodikova S, Howard-Jones AR: Biological formation of pyrroles: nature's logic and enzymatic machinery. Nat, Prod. Rep. 23, 517-531 (2006).
25. Mo S, Kim BS, Reynolds KA: Production of branched-chain alkylprodiginines in S. coelicolor by replacement of the 3-ketoacyl ACP synthase III initiation enzyme RedP. Chem. Biol. 12, 191-200 (2005).
26. Tsao SW, Rudd BA, He XG, Chang CJ, Floss HG: Identification of a red pigment from Streptomyces coelicolor A3(2) as a mixture of prodigiosin derivatives. J. Antibiot. (Tokyo) 38, 128-131 (1985).
27. Gummert JF, Ikonen T, Morris RE: Newer immunosuppressive drugs: a review. J. Am. Soc. Nephrol. 10, 1366-1380 (1999).
28. Thomson AW and Starzl TE: New immunosuppressive drugs: mechanistic insights and potential therapeutic advances. Ammunol Rev. 136, 71-98 (1993).
29. Nakamura A, Nagai K, Suzuki S, Ando K, Tamura G: A novel method of screening for immunomodulating substances, establishment of an assay system and its application to culture broths of microorganisms. J. Antibiot. (Tokyo) 39, 1148-1154 (1986).
30. Nakamura A, Magae J, Tsuji RF, Yamasaki M, Nagai K: Suppression of cytotoxic T cell induction in vivo by prodigiosin 25-C. Transplantation 47, 1013-1016 (1989).
31. Tsuji RF, Yamamoto M, Nakamura A et al.: Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system. J. Antibiot. (Tokyo). 43, 1293-1301 (1990).
32. Tsuji RF, Magae J, Yamashita M, Nagai K, Yamasaki M: Immunomodulating properties of prodigiosin 25-C, an antibiotic which preferentially suppresses induction of cytotoxic T cells. J. Antibiot. (Tokyo). 45, 1295-1302 (1992).
33. Songia S, Mortellaro A, Taverna S et al.: Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets. J. Immunol. 158, 3987-3995 (1997).
34. Sigal NH and Dumont FJ: Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu. Rev. Immunol. 10, 519-560 (1992).
35. Han SB, Kim HM, Kim YH et al.: T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens. Int. J. Immunopharmacol. 20, 1-13 (1998).
36. Han SB, Park SH, Jeon YJ, Kim YK, Kim HM, Yang KH: Prodigiosin blocks T cell activation by inhibiting interleukin-2Rα expression and delays progression of autoimmune diabetes and collagen-induced arthritis. J. Pharmacol. Exp. Ther. 299, 415-425 (2001).
37. Han SB, Lee CW, Yoon YD et al.: Effective prevention of lethal acute graft-versus-host disease by combined immunosuppressive therapy with prodigiosin and cyclosporine A. Biochem. Pharmacol. 70, 1518-1526 (2005).
38. Magae J, Miller MW, Nagai K, Shearer GM: Effect of metacycloprodigiosin, an inhibitor of killer T cells on murine skin and heart transplants. J. Antibiot. (Tokyo) 49, 86-90 (1996).
39. Azuma T Watanabe N, Yagisawa H, Hirata H, Iwamura M, Kobayashi Y: Induction of apoptosis of activated murine splenic T cells by cycloprodigiosin hydrochloride, a novel immunosuppressant. Immunopharmacology 46, 29-37 (2000).
40. Nakai K, Hamada Y, Kato Y, Yamamoto D, Hirata H, Hioki K: Cycloprodigiosin hydrochloride as an immunosuppressant in rat small bowel transplantation. Transplant Proc. 32, 1324-1325 (2000).
41. D'Alessio R, Bargiotti A, Carlini O et al.: Synthesis and immunosuppressive activity of novel prodigiosin derivatives. J. Med. Chem. 43, 2557-2565 (2000).
42. Mortellaro A, Songia S, Gnocchi P et al.: New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-κB and AP-1 activation. J. Immunol. 162, 7102-7109 (1999).
43. Stepkowski SM, Nagy ZS, Wang ME et al.: PNU156804 inhibits Jak3 tyrosine kinase and rat heart allograft rejection. Transplant Proc. 33, 3272-3273 (2001).
44. Stepkowski SM, Erwin-Cohen RA, Behbod F et al.: Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 99, 680-689 (2002).
45. Wang M, Kirken R, Behbod F, Erwin-Cohen R, Stepkowski SM, Kahan BD: Inhibition of Jak3 tyrosine kinase by PNU156804 blocks rat heart allograft rejection. Transplant Proc. 33, 201 (2001).
46. - symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Hepatology 30, 894-902 (1999).
47. Montaner B, Navarro S, Pique M et al.: Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines. Br. J. Pharmacol. 131, 585-593 (2000).
48. Montaner B and Pérez-Tomás R: Prodigiosin-induced apoptosis in human colon cancer cells. Life Sci. 68, 2025-2036 (2001).
49. Regourd J, Ali AA, Thompson A: Synthesis and anti-cancer activity of C-ring-functionalized prodigiosin analogues. J. Med. Chem. 50, 1528-1536 (2007).
50. Manderville RA: Synthesis, proton-affinity and anti-cancer properties of the prodigiosin-group natural products. Curr. Med. Chem. Anticanc. Agents. 1, 195-218. (2001).
51. Zhang J, Shen Y, Liu J, Wei D: Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochem. Pharmacol. 69, 407-414 (2005).
52. Soto-Cerrato V, Liagostera E, Montaner B, Scheffer GL, Pérez-Tamás R: Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. Biochem. Pharmacol. 68, 1345-1352 (2004).
53. Liagostera E, Soto-Cerrato V, Joshi R, Montaner B, Gimenez-Bonafe P, Pérez-Tomás R: High cytotoxic sensitivity of the human small cell lung doxorubicin-resistant carcinoma (GLC4/ADR) cell line to prodigiosin through apoptosis activation. Anticancer Drugs 16, 393-399 (2005).
54. Susin SA, Daugas E, Ravagnan L et al.: Two distinct pathways leading to nuclear apoptosis. J. Exp. Med. 192, 571-580 (2000).
55. Liagostera E, Soto-Cerrato V, Montaner B, Perez-Tomás R: Prodigiosin induces apoptosis by acting on mitochondria in human lung cancer cells. Ann. NY Acad. Sci. 1010, 178-181 (2003).
56. Monge M, Vilaseca M, Soto-Cerrato V, Montaner B, Giralt E, Pérez-Tomás R: Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line. Invest. New Drugs 25, 21-29 (2007).
57. Montaner B and Pérez-Tomás R: Prodigiosin induces caspase-9 and caspase-8 activation and cytochrome C release in Jurkat T cells. Ann. NY Acad. Sci. 973, 246-249. (2002).
58. - symporter, induces apoptosis and differentiation in HL-60 cells. Int J Cancer. 88, 121-128 (2000).
59. Kamata K, Okamoto S, Oka S, Kamata H, Yagisawa H, Hirata H: Cycloprodigiosin hydrocloride suppresses tumor necrosis factor (TNF)α-induced transcriptional activation by NF-κB. FEBS Lett. 507, 74-80 (2001).
60. Tanigaki K, Sasaki S, Ohkuma S: In bafilomycin A1-resistant cells, bafllomycin A1 raised lysosomal pH and both prodigiosins and concanamycin A inhibited growth through apoptosis. FEBS Lett. 537, 79-84 (2003).
61. Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-1912 (2002).
62. Montaner B and Pérez-Tomás R: The cytotoxic prodigiosin induces phosphorylation of p38-MAPK but not of SAPK/JNK. Toxicol Lett. 129, 93-98. (2002).
63. Nakashima T, Tamura T, Kurachi M, Yamaguchi K, Oda T: Apoptosis-mediated cytotoxicity of prodigiosin-like red pigment produced by gamma-Proteobacterium and its multiple bioactivities. Biol. Pharm. Bull. 28, 2289-2295 (2005).
64. Ramoneda BM and Pérez-Tomás R: Activation of protein kinase C for protection of cells against apoptosis induced by the immunosuppressor prodigiosin. Biochem. Pharmacol. 63, 463-469 (2002).
65. Soto-Cerrato V, Vinals F, Lambert JR, Pérez-Tomás R: The anticancer agent prodigiosin induces p21 (WAF1/CIP1) expression via transforming growth factor-β receptor pathway. Biochem. Pharmacol. 74, 1340-1349 (2007).
66. Soto-Cerrato V, Vinals F, Lambert JR, Kelly JA, Pérez-Tomás R: Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3β activity in human breast cancer cells. Mol. Cancer Ther. 6, 362-369 (2007).
67. Fürstner A, Reinecke K, Prinz H, Waldmann H: The core structures of roseophilin and the prodigiosin alkaloids define a new class of protein tyrosine phosphatase inhibitors. Chembiochem. 5, 1575-1579 (2004).
68. - symporters that uncouple proton translocators. J. Biol. Chem. 273, 21455-21462 (1968).
69. - requirement for Inhibition of vacuolar acidification by cycloprodigiosin in situ. Plant Cell Physiol. 41, 857-863 (2000).
70. +-ATPase inhibitors on CTL-mediated cytotoxicity. Immunol Lett. 55, 139-144 (1997).
71. +-ATPase Inhibitors. J. Antibiot. (Tokyo) 45, 1618-1625 (1992).
72. +-ATPase, inhibits vacuolar acidification and affects glycoprotein processing. FEBS Lett. 359, 53-59 (1995).
73. Kawauchi K, Shibutani K, Yagisawa H et al.: A possible immunosuppressant, cycloprodigiosin hydrochloride, obtained from Pseudoalteromonas denitrificans. Biodiem. Biophys.& Res. Commun. 237, 543-547 (1997).
74. - symport. Biochem J 334 ( Pt 3), 731-741 (1998).
75. +) -ATPase by prodigiosins. Biochem. Pharmacol. 60, 1855-1863 (2000).
76. - symport activity. Biochem (Tokyo). 124, 547-556 (1999).
77. Francisco R, Pérez-Tomás R, Gimenez-Bonafe P. Soto-Cerrato V, Gimenez-Xavier P, Ambrosio S: Mechanisms of prodigiosin cytotoxicity in human neuroblastoma cell lines. Eur. J. Pharmacol. (2007).
78. Gale PA: Amidopyrroles: from anion receptors to membrane transport agents. Chem. Commun. (Camb). 3761-3772 (2005).
79. - by a synthetic prodigiosin mimic. Chem. Commun. (Camb). 3773-3775 (2005).
80. Fürstner A, Grabowski J, Lehmann CW, Kataoka T, Nagai K: Synthesis and biological evaluation of nonylprodigiosin and macrocyclic prodigiosin analogues. Chembiochem. 2, 60-68 (2001).
81. Diaz RI, Regourd J, Santacroce PV, Davis JT, Jakeman DL, Thompson A: Chloride anion transport and copper-mediated DNA cleavage by C-ring functionalized prodigiosenes. Chem. Commun. (Camb). 2701-2703 (2007).
82. Sessler JL, Eller LR, Cho WS et al.: Synthesis, anion-binding properties, and In vitro anticancer activity of prodigiosin analogues. Angew. Chem. Int. Ed. Engl. 44, 5989-5992 (2005).
83. Seganish JL and Davis JT. Prodigiosin is a chloride carrier that can function as an anion exchanger. Chem. Commun. (Camb). 5781-5783 (2005).
84. - symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells. Life Sci. 78, 121-127 (2005).
85. Melvin MS, Ferguson DC, Lindquist N, Mandervine RA: DNA binding by 4-methoxypyrrolic natural products. preference for intercalation at AT sites by tambjamine E and prodigiosin. J. Org. Chem. 64, 6861-6869 (1999).
86. Melvin MS, Tomlinson JT, Saluta GR, Kucera GL, Lindquist N, Manderville RA: Double-strand DNA Cleavage by copper-prodigiosin. J Am. Chem. Soc. 122, 6333-6334 (2000).
87. Melvin MS, Wooton KE, Rich CC et al.: Copper-nuclease efficiency correlates with cytotoxicity for the 4-methoxypyrrolic natural products. J Inorg. Biochem. 87, 129-135 (2001).
88. Melvin MS, Tomlinson JT, Park G et al.: Influence of the A-ring on the proton affinity and anticancer properties of the prodigiosins. Chem. Res. Toxicol. 15, 734-741 (2002).
89. Melvin MS, Calcutt MW, Noftle RE, Manderville, RA: Influence of the A-ring on the redox and nuclease properties of the prodigiosins: importance of the bipyrrole moiety in oxidative DNA cleavage. Chem. Res. Toxicol. 15, 742-748 (2002).
90. Fürstner A and Grabowski EJ: Studies on DNA cleavage by cytotoxic pyrrole alkaloids reveal the distinctly different behavior of roseophilin and prodigiosin derivatives. Chem biochem. 2, 706-709 (2001).
91. Park G, Tomlinson JT, Melvin MS, Wright MW, Day CS, Manderville RA: Zinc and copper complexes of prodigiosin: implications for copper-mediated double-strand DNA cleavage, Org. Lett. 5, 113-116. (2003).
92. Montaner B, Castillo-Avila W, Martinell M et al.: DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin, Toxicol. Sci. 85, 870-879 (2005).
93. Baldino CM, Parr J, Wilson CJ, Ng SC, Yohannes D, Wasserman HH: Indoloprodigiosins from the C-10 bipyrrolic precursor: new antiproliferative prodigiosin analogs. Bioorg. Med. Chem. Lett. 16, 701-704 (2006).
94. Riley DJ, Lee EY, Lee WH: The retinoblastoma protein: more than a tumor suppressor. Annu. Rev Cell Biol. 10, 1-29 (1994).
95. Gesbert F, Delespine-Carmagnat M, Bertoglio J: Recent advances in the understanding of interieukin-2 signal transduction. J. Clin. Immunol. 18, 307-320 (1998).
96. Benczik M and Gaffen SL: The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol. Invest. 33, 109-142 (2004).
97. Miyazaki T Liu ZJ, Kawahara A et al.: Three distinct IL-2 signaling-pathways mediated by bcl-2. c-myc, and Ick cooperate In hematopoietic cell proliferation. Cell 81, 223-231 (1995).
98. Adcock IM: Transcription factors as activators of gene transcription: AP-1 and NF-κB. Monaldi. Arch. Chest Dis. 52, 178-186 (1997).
99. Brasier AR: The NF-κB regulatory network. Cardiovarc. Toxicol. 6, 111-130 (2006).
100. Baldwin ASJ: The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunology. 14 (1996).
101. Leonard WJ and O'Shea JJ: Jaks and STATs: biological Implications. Annu. Rev. Immunol. 16, 293-322 (1998).
102. Pérez-Tomás R and Montaner B: Effects of the proapoptotic drug prodigiosin on cell cycle-related proteins in Jurkat T cells. Histol. Histopathol. 18, 379-385 (2003).
103. Weissman KJ: Mutasynthesis - uniting chemistry and genetics for drug discovery. Trends Biotechnol. 25, 139-142 (2007).
104. Weist S and Sussmuth RD: Mutational biosynthesis - a tool for the generation of structural diversity in the biosynthesis of antibiotics. Appl. Microbiol. Biotechnol. 68. 141-150 (2005).
105. Park G, Tomlinson JT, Misenheimer JA, Kucera GL, Manderville RA: Photo-induced cytotoxicity of prodigiosin analogues. Bull. Korean Chem. Soc. 28, 49-52 (2007).
106. Tomlinson JT Park G, Misenheimer JA, Kucera GL, Hesp K, Manderville, RA: Photoinduced cytotoxicity and thioadduct formation by a prodigiosin analogue. Org. Lett. 8, 4951-4954 (2006).
107. Rioux E, Billot X, Dairt K et al.: SAR study on aryl and heteroaryl bipyrrole inhibitors of Bcl antiapoptotic proteins with potent antitumor activity in vivo. J Mexican Chem. Soc. (IUPAC-ICOS-16 special issue) 50, 209 (2006).
108. Pérez-Galán P, Roué G, Villamor N, Campo E, Colomer D: The BH3-mirnetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109, 4441-4449 (2007).
109. Zinkel S, Gross A, Yang E: Bcl2 family in DNA damage and cell cycle control. Call Death Differ. 13, 1351-1359 (2006).
110. Reed JC: Apoptosis-targeted therapies for cancer. Cancer Cell. 3, 17-22 (2003).
111. Trudel S, Li-ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK Preclinical studies of the pan-Bcl inhibitor obatoclax (GXO 15-070) in multiple myeloma. Blood 109, 5430-5438 (2007).
112. Campás C, Cosialls AM, Barragán M et al.: Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Emp. Hematol. 34, 1663-1669 (2006).
113. O'Brien S, Marshall J, Viallet J, Kantarjian H: Small molecule pan-Bc12 family inhibitor Obatoclax (GX15-070): overview of clinical Phase I study results. Chemotherapy Foundation Symposium (2006).
114. Diaz-Ruiz C, Montaner B, Pérez-Tomás R: Prodigiosin induces cell death and morphological changes indicative of apoptosis in gastric cancer cell line HGT-1. Histol. Histopathol. 16, 415-421 (2001).
115. - symporter, induces apoptosis in human colon cancer cell lines in vitro. Oncol. Rep. 8, 821-824 (2001).
116. Liu R, Cui CB, Duan L, Gu QQ, Zhu WM: Potent in vitro anticancer activity of metacycloprodigiosin and undecylprodigiosin from a sponge-derived actinomycete Saccharopolyspora sp. nov. Arch. Pharm. Res. 28, 1341-1344 (2005).
117. Deorukhkar AA, Chander R. Ghosh SB, Sainis KB: Identification of a red-pigmented bacterium producing a potent anti-tumor N-alkylated prodigiosin as Serratia marcecens. Res. Microbiol. 158, 399-404 (2007).
118. Deorukhkar AA, Chander R, Pandey R, Sainis KB: A novel N-alkylated prodigiosin analogue induced death in tumour cell through apoptosis or necrosis depending upon the cell type. Cancer Chemother. Pharmacol. (2007).